DLEC1 Inhibitors
Chemical inhibitors of DLEC1 can exert their inhibitory action through multiple mechanisms by targeting various signaling pathways with which DLEC1 is associated. Erlotinib and Gefitinib, for instance, are EGFR tyrosine kinase inhibitors that disrupt the EGFR signaling pathway. DLEC1's function is closely linked with this pathway, and as such, the inhibition of EGFR by these chemicals leads to a decrease in the downstream signaling events essential for DLEC1 activity. Similarly, Lapatinib, a dual tyrosine kinase inhibitor, impairs both EGFR and HER2/neu receptors. By impeding these receptors, Lapatinib disrupts the necessary downstream signaling, reducing DLEC1 activity. Afatinib further extends this inhibition as an irreversible inhibitor of the EGFR family, suggesting a more sustained reduction in the EGFR-mediated pathways upon which DLEC1 depends.
Additionally, multi-targeted inhibitors like Sorafenib and Sunitinib inhibit receptors such as VEGFR and PDGFR, which play a role in the pathways that facilitate DLEC1 functionality. By blocking these receptors, these inhibitors can indirectly prevent the action of DLEC1. Dasatinib, which targets BCR-ABL tyrosine kinase and SRC family kinases, can also impede the upstream regulators of pathways involving DLEC1, leading to a reduction in the protein's functional activity. Crizotinib's inhibition of ALK, ROS1, and c-Met/HGFR tyrosine kinases results in a similar downstream effect on the pathways linked to DLEC1. Other inhibitors that function in a comparable manner include Pazopanib, Axitinib, and Vandetanib, which target VEGFRs and other kinases involved in angiogenesis, a process with which DLEC1 is associated. By disrupting these pathways, these inhibitors contribute to the functional inhibition of DLEC1. Lastly, Nilotinib, another selective tyrosine kinase inhibitor, suppresses PDGFR and c-KIT in addition to BCR-ABL, further demonstrating how multi-kinase inhibition can lead to a reduction in DLEC1 activity by obstructing the requisite signaling pathways for its functionality.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $87.00 $135.00 $293.00 $505.00 $3827.00 | 42 | |
Erlotinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. DLEC1 has been implicated in EGFR signaling pathways. By inhibiting EGFR, Erlotinib can reduce the downstream signaling that may be crucial for the activity of DLEC1, leading to its functional inhibition. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $420.00 | 32 | |
Lapatinib is a dual tyrosine kinase inhibitor that targets both EGFR and HER2/neu receptors. Since DLEC1 is associated with EGFR-mediated signaling, inhibition of this pathway by Lapatinib would result in reduced activation of downstream components that facilitate DLEC1 function. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Gefitinib selectively inhibits the EGFR tyrosine kinase, which is involved in the proliferation and survival of cancer cells. By targeting EGFR, Gefitinib could disrupt the signaling pathways that DLEC1 is a part of, leading to a decrease in DLEC1's functional activity. | ||||||
Afatinib-d4 | 850140-72-6 (unlabeled) | sc-481821 | 10 mg | $4665.00 | ||
Afatinib is an irreversible inhibitor of the EGFR family of tyrosine kinases. Its action can lead to the downregulation of EGFR signaling, potentially diminishing the functional activity of DLEC1 which operates within this pathway. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib is a kinase inhibitor that targets multiple receptors, including VEGFR and PDGFR. By inhibiting these receptors, Sorafenib can affect the pathways that are essential for the functionality of DLEC1, thereby inhibiting its action. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $153.00 $938.00 | 5 | |
Sunitinib is a multi-targeted receptor tyrosine kinase inhibitor, affecting pathways involved in tumor growth and angiogenesis. Inhibiting these pathways can indirectly lead to the functional inhibition of DLEC1 by disrupting its associated signaling. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a BCR-ABL tyrosine kinase inhibitor and also inhibits SRC family kinases. As SRC kinases can be upstream regulators in pathways involving DLEC1, Dasatinib can impede the pathways necessary for DLEC1's function. | ||||||
Pazopanib | 444731-52-6 | sc-396318 sc-396318A | 25 mg 50 mg | $130.00 $182.00 | 2 | |
Pazopanib is a multi-tyrosine kinase inhibitor that affects VEGFR, PDGFR, and c-KIT. These are involved in angiogenesis and tumor growth, pathways in which DLEC1 is active. Inhibition by Pazopanib can, therefore, reduce the functional activity of DLEC1. | ||||||
Vandetanib | 443913-73-3 | sc-220364 sc-220364A | 5 mg 50 mg | $167.00 $1353.00 | ||
Vandetanib inhibits VEGFR, EGFR, and RET tyrosine kinases. The inhibition of these kinases can interfere with the signaling pathways necessary for DLEC1's activity, leading to its functional inhibition. | ||||||
Nilotinib | 641571-10-0 | sc-202245 sc-202245A | 10 mg 25 mg | $209.00 $413.00 | 9 | |
Nilotinib is a selective BCR-ABL tyrosine kinase inhibitor, but it also inhibits PDGFR and c-KIT. By targeting these kinases, Nilotinib can suppress the pathways critical for DLEC1's functionality, effectively inhibiting the protein. | ||||||